Today Roche announced positive results from our Phase I clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of #obesity and type 2 #diabetes. The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo. Learn more here: https://bit.ly/3wKVSgD
About us
Carmot has been acquired by Roche in early 2024, making the company a member of the Roche Group. Carmot Therapeutics is a clinical-stage biotechnology company that is focused on advancing life-changing therapeutics for people with obesity and diabetes. We are utilizing Chemotype Evolution, a pioneering drug discovery platform, to identify novel incretin receptor signaling targets to develop a broad pipeline of therapeutics that have the potential to produce significant weight loss and improved glycemic control. We have three clinical candidates: CT-388, CT-868 and CT-996.
- Website
-
http://carmot-therapeutics.us/
External link for Carmot Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Berkeley
- Type
- Privately Held
- Specialties
- Pharmaceuticals
Locations
-
Primary
Get directions
Berkeley, US
Employees at Carmot Therapeutics, Inc.
Updates
-
Join us in raising awareness for #WorldObesityDay. Starting a conversation can help us bring understanding to others and make it easier to build momentum towards action. As more than 1 billion people in the world today are living with #obesity, we remain committed to developing life-changing therapeutics. Learn more here: https://lnkd.in/eS38U52 #LetsTalkAboutObesity
-
-
Today we announced the completion of our acquisition by Roche, making Carmot part of Roche’s Pharmaceutical Division. Together we’ll continue to advance three clinical-stage assets in #obesity and #diabetes. Learn more: https://bit.ly/48QGwVT
-